Dexcom Inc (DXCM) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, Dexcom reported revenue of $4.66B, up 15.6% from $4.03B the year before. Net income was $836.3M (a 17.9% net margin), or $2.09 per diluted share. Gross margin was 60.1% and operating margin was 19.6%. Operating activities generated $1.44B of cash, leaving $1.08B of free cash flow. At fiscal year end, Dexcom held $6.34B in total assets against $3.59B in total liabilities, including $917.7M of cash and equivalents.
Open the full interactive Dexcom financials → Quarterly statements, key ratios, valuation history and price charts.
Dexcom Key Stats
| Share Price | $85.06 |
|---|---|
| Market Cap | $33.18B |
| P/E Ratio | 40.7 |
| Revenue YoY Growth | +15.6% |
| 52-Week Range | $54.84 – $92.34 |
| Shares Outstanding | 382.2 million (basic, 2026 Q2) |
Dexcom Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.93B | $2.45B | $2.91B | $3.62B | $4.03B | $4.66B |
| Cost of Goods Sold | $646.6M | $768.0M | $1.03B | $1.33B | $1.59B | $1.86B |
| Gross Profit | $1.28B | $1.68B | $1.88B | $2.29B | $2.44B | $2.80B |
| Operating Income | $299.5M | $265.8M | $391.2M | $597.7M | $600.0M | $911.8M |
| Pre-Tax Income | $225.0M | $173.9M | $390.8M | $710.4M | $709.0M | $1.09B |
| Income Tax | -$268.6M | $19.2M | $49.6M | $168.9M | $132.8M | $252.1M |
| Net Income | $493.6M | $154.7M | $341.2M | $541.5M | $576.2M | $836.3M |
| Diluted EPS | $1.26 | $0.39 | $0.82 | $1.30 | $1.42 | $2.09 |
Dexcom Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1.21B | $1.26B | $1.19B | $1.31B |
| Net Income | $283.8M | $267.3M | $199.5M | $249.1M |
| Diluted EPS | $0.70 | $0.66 | $0.51 | $0.64 |
Dexcom Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $817.6M | $1.05B | $642.3M | $566.3M | $606.1M | $917.7M |
| Current Assets | $3.42B | $3.68B | $3.67B | $4.43B | $4.30B | $4.03B |
| Total Assets | $4.29B | $4.86B | $5.39B | $6.26B | $6.48B | $6.34B |
| Current Liabilities | $614.1M | $720.8M | $1.84B | $1.56B | $2.93B | $2.14B |
| Total Long-Term Debt | $1.67B | $1.70B | $1.97B | $2.43B | $2.44B | $1.24B |
| Total Liabilities | $2.46B | $2.61B | $3.26B | $4.20B | $4.38B | $3.59B |
| Shareholders' Equity | $1.83B | $2.25B | $2.13B | $2.07B | $2.10B | $2.75B |
Dexcom Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $475.6M | $442.5M | $669.5M | $748.5M | $989.5M | $1.44B |
| Cash From Investing | -$1.02B | -$216.1M | -$521.5M | -$507.2M | -$207.5M | $536.0M |
| Cash From Financing | $912.1M | $10.4M | -$552.5M | -$318.6M | -$734.8M | -$1.69B |
| Free Cash Flow | $276.6M | $53.3M | $304.7M | $511.9M | $630.7M | $1.08B |
Figures from Dexcom's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Dexcom financials page for every line item.
Dexcom Company Profile
| Ticker | DXCM |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001093557 |
Frequently Asked Questions
What was Dexcom's revenue in fiscal 2025?
Dexcom (DXCM) reported revenue of $4.66B for fiscal 2025.
What is Dexcom's annual revenue history?
Dexcom's annual revenue by fiscal year: 2020: $1.93B; 2021: $2.45B; 2022: $2.91B; 2023: $3.62B; 2024: $4.03B; 2025: $4.66B.
What was Dexcom's net income in fiscal 2025?
Dexcom reported net income of $836.3M for fiscal 2025.
What was Dexcom's earnings per share (EPS) in fiscal 2025?
Dexcom's diluted EPS was $2.09 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Dexcom generate in fiscal 2025?
Dexcom generated $1.08B of free cash flow in fiscal 2025.
What was Dexcom's revenue last quarter?
In its most recent reported quarter (2026 Q2), Dexcom reported revenue of $1.31B.
How much debt does Dexcom have?
Dexcom reported $1.24B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Dexcom are outstanding?
Dexcom reported a weighted average of 382.2 million basic shares outstanding in 2026 Q2.
What is Dexcom's market cap?
Based on its latest closing price, Dexcom (DXCM) has a market capitalization of about $33.18B.
When does Dexcom's fiscal year end?
Dexcom's fiscal year end, as registered with the SEC, is December 31.
Where is Dexcom headquartered?
Dexcom lists its business address in San Diego, California in its SEC filings.